EURORDIS Summer School for patient advocates in clinical trials and drug development by Mavris, Maria & Bignami, Fabrizia
POSTER PRESENTATION Open Access
EURORDIS Summer School for patient advocates
in clinical trials and drug development
Maria Mavris
*, Fabrizia Bignami
From 5th European Conference on Rare Diseases (ECRD 2010)
Krakow, Poland. 13-15 May 2010
EURORDIS, the European Organisation for Rare Dis-
eases launched this new initiative in 2008 with the sup-
port of the Drug Information Association (DIA)
Philanthropy programme, the Association Française con-
tre les Myopathies (AFM), Fundacio Dr. Robert and the
European Agency for Health and Consumers (EAHC).
Many of EURORDIS’ members are extensively involved
in EU decision-making processes in the European Medi-
cines Agency (EMA), including as experts, patients’
representatives and/or members of scientific committees
and working parties.
The aim of the EURORDIS Summer School is to assist
these and future patient advocates to i) better promote
drug development, ii) be involved in regulatory affairs,
and to iii) guarantee access to treatments and iv)
improve the quality of orphan drug information to
patients.
The 4-day programme consists of:
1) a description of the drug development process
from clinical trials to regulatory stages and includes
statistics, ethics and post-marketing aspects.
2) a description of the committees and working par-
ties at the EMA with particular emphasis on the role
of patients’ representatives and
3) the role of EURORDIS and in particular of its
“Task Forces” whose volunteers can also be involved
in the above activities.
The aim of the Summer School is to:
1. to establish a forum for exchange of informa-
tion, education and training for these high-level
selected patient advocates from a wide range of
rare diseases across Europe;
2. to enhance the experience they have gained
and their leadership capacities.
As patient advocates are increasingly involved in all
aspects of drug development (from research to eco-
nomic aspects), there is a growing need to provide sup-
port and training in these areas. The EURORDIS
Summer School not only addresses these needs but also
provides the means for advocates to interact with each
other as well as with regulators, academic partners and
industry. In addition to the learning experience, the
Summer School provides an excellent forum for in-
depth exchange of information and experiences, all in
the beautiful city of Barcelona.
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